Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock

Key Points

• Major shareholder Group Walters bought 4.335 million Zentalis Pharmaceuticals shares at an average price of $3.50, investing approximately $15.17 million and increasing its position by 32.09% to 17.84 million shares.
• ZNTL shares rose 3.8% to $3.82, but the company reported a quarterly loss of $0.59 per share, missing analyst expectations of a $0.49 loss. Analysts expect a full-year loss of $2.14 per share.
• Analyst sentiment is mixed, with four Buy, four Hold and one Sell rating; the consensus rating is Hold with a $6.75 price target, while several institutions have recently increased their holdings.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) major shareholder Group Walters bought 4,335,000 shares of the business's stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the purchase, the insider owned 17,844,973 shares of the company's stock, valued at approximately $62,457,405.50. The trade was a 32.09% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Zentalis Pharmaceuticals Stock Up 3.8%

Shares of NASDAQ:ZNTL traded up $0.14 on Wednesday, hitting $3.82. 1,694,797 shares of the company traded hands, compared to its average volume of 1,645,934. The stock has a 50 day simple moving average of $4.34 and a 200-day simple moving average of $3.65. The company has a market cap of $273.78 million, a PE ratio of -1.96 and a beta of 1.92. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.21 and a 52 week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.10). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current year.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ZNTL. 5AM Venture Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 705.7% in the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company's stock worth $5,330,000 after acquiring an additional 3,457,913 shares during the period. BlackRock Inc. bought a new position in Zentalis Pharmaceuticals during the second quarter valued at approximately $18,205,000. Millennium Management LLC boosted its holdings in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company's stock worth $4,386,000 after purchasing an additional 19,768 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Zentalis Pharmaceuticals by 24.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company's stock worth $3,893,000 after purchasing an additional 558,390 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Wall Street Zen cut Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Mizuho started coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an "outperform" rating and a $8.00 target price on the stock. Finally, Rodman & Renshaw started coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a "buy" rating and a $11.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $6.75.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source